NCT06331533View on ClinicalTrials.gov

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

June 1, 2023

Conditions
Erythematotelangiectatic Rosacea
Interventions
DRUG

Botulinum toxin A

Intradermal botulinum toxin A was applied to the treatment side

DRUG

Placebo

NaCl was injected into the placebo side

Trial Locations (1)

34098

Istanbul Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Istanbul Training and Research Hospital

OTHER_GOV